高甘油三酯但不符合他汀适应证者的初级预防未满足需求
基于哥本哈根一般人群研究(2003-2015)的58 547名40-65岁无ASCVD、糖尿病且未用他汀的个体,按2016 ESC/EAS指南分为他汀明确适用、不适用且甘油三酯≥3.0 mmol/L、不适用且甘油三酯<3.0 mmol/L三组。随访显示,不适用他汀但甘油三酯≥3.0 mmol/L者的ASCVD风险与他汀适用者相似,提示当前指南他汀适应证存在未满足的初级预防需求。
要点
- 不适用他汀但甘油三酯≥3.0 mmol/L者10年MACE风险为5.7%,接近他汀适用者的7.6%。
- 该人群10年MI风险为3.0%,与他汀适用者的3.3%相近。
- 提示需扩展他汀适应证指南,并考虑在该人群开展安慰剂对照随机临床试验。
核心结论
- 不适用他汀但甘油三酯≥3.0 mmol/L(264 mg/dL)的个体,其ASCVD风险与根据2016 ESC/EAS指南他汀明确适用的个体相似。
- 这反映了初级预防的未满足需求,呼吁扩展他汀适应证指南,并提示在高甘油三酯人群开展安慰剂对照随机临床试验的潜力。
研究设计与样本
- 基于哥本哈根一般人群研究(2003-2015)的当代人群队列研究。
- 纳入58 547名年龄40-65岁、基线无ASCVD、无糖尿病且未使用他汀的个体。
- 按2016 ESC/EAS指南分为他汀明确适用(14%)、不适用且甘油三酯≥3.0 mmol/L(7%)、不适用且甘油三酯<3.0 mmol/L(79%)三组。
- 随访共456 057人年,观察主要不良心血管事件(MACE)和心肌梗死(MI)。
主要发现
- 随访期间1770人发生MACE,734人发生MI。
- 至70岁时,不适用他汀且甘油三酯<3.0 mmol/L、不适用他汀且甘油三酯≥3.0 mmol/L、他汀适用三组的MACE累积发生率分别为8.1%(95%CI 7.3-8.9%)、14.6%(12.6-16.8%)、16.5%(14.0-19.3%)。
- 三组MI累积发生率分别为3.0%(2.7-3.3%)、7.8%(6.4-9.5%)、7.1%(5.9-8.4%)。
- 三组10年MACE风险分别为2.8%(2.6-3.0%)、5.7%(4.9-6.6%)、7.6%(6.9-8.3%),中位年龄分别为51、51、60岁。
- 三组10年MI风险分别为1.0%(0.9-1.1%)、3.0%(2.4-3.7%)、3.3%(2.8-3.7%)。
关键数值与推荐
- 2016 ESC/EAS指南他汀明确适用者占14%,不适用且甘油三酯≥3.0 mmol/L(264 mg/dL)者占7%,不适用且甘油三酯<3.0 mmol/L者占79%。
- 不适用他汀但甘油三酯≥3.0 mmol/L者10年MACE风险5.7%(4.9-6.6%),与他汀适用者7.6%(6.9-8.3%)相近。
临床怎么用
- 对不适用他汀但甘油三酯≥3.0 mmol/L(264 mg/dL)的个体,应认识到其ASCVD风险与他汀适用者相似。
- 考虑将该类高甘油三酯人群纳入更积极的初级预防管理,并关注指南他汀适应证的扩展需求。
- 支持在高甘油三酯且不符合他汀适应证人群中开展安慰剂对照随机临床试验以评估干预获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To identify individuals at high risk of atherosclerotic cardiovascular disease (ASCVD), who are not definite statin eligible according to the 2016 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines, based on high concentrations of plasma triglycerides. METHODS AND RESULTS: From the Copenhagen General Population Study (2003-2015) 58 547 individuals aged 40-65 and free of ASCVD, diabetes, and statin use at baseline were included. Of these, 14% were definite statin eligible, 7% were not eligible and had triglycerides ≥3.0 mmol/L (264 mg/dL), and 79% were not statin eligible and had triglycerides <3.0 mmol/L (264 mg/dL). During 456 057 person-years of follow-up, 1770 individuals experienced a major adverse cardiovascular event (MACE) and 734 experienced a myocardial infarction (MI). The cumulative incidences of MACE at age 70 were 8.1% (95% confidence interval 7.3-8.9%) and 14.6% (12.6-16.8%) in statin non-eligible individuals with triglycerides <3.0 mmol/L (264 mg/dL) and ≥3.0 mmol/L (264 mg/dL), and 16.5% (14.0-19.3%) in statin eligible individuals. Corresponding cumulative incidences of MI were 3.0% (2.7-3.3%), 7.8% (6.4-9.5%), and 7.1% (5.9-8.4%), respectively. The estimated 10-year risks of MACE were 2.8% (2.6-3.0%) and 5.7% (4.9-6.6%) in statin non-eligible individuals with triglycerides <3.0 mmol/L (264 mg/dL) and ≥3.0 mmol/L (264 mg/dL), and 7.6% (6.9-8.3%) in statin eligible individuals; the median age in these three groups were 51, 51, and 60 years, respectively. Corresponding risks of MI were 1.0% (0.9-1.1%), 3.0% (2.4-3.7%), and 3.3% (2.8-3.7%), respectively. CONCLUSION: Statin non-eligible individuals with triglycerides ≥3.0 mmol/L (264 mg/dL) had risk of ASCVD similar to statin eligible individuals, defined according to the 2016 ESC/EAS guidelines. This illustrates an unmet need for primary prevention, calling for expansion of guidelines on statin eligibility, and the potential for placebo-controlled randomized clinical trials in individuals with hypertriglyceridaemia.
引用
- Madsen CM, Varbo A, Nordestgaard BG, et al. Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study. Eur Heart J. 2018. PMID: 29182745. doi:10.1093/eurheartj/ehx659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。